Yahoo
NYSE - Delayed Quote USD

Teva Pharmaceutical Industries Limited (TEVA)

36.36 -0.26 (-0.71%)
At close: September 4 at 4:00:03 PM EDT
37.19 +0.83 (+2.28%)
After hours: September 4 at 7:59:01 PM EDT
Trade TEVA on Coinbase
Chart Range Bar
Loading chart for TEVA

What's happening with TEVA?

54m ago
Powered by Yahoo Scout

Teva is making strategic moves with a potential $125 millionbid for BioXcel’s assets while also reporting positive results for its anti-IL-15 antibody TEV-408 in celiac disease studies. The company is involved in significant drug pricing agreements aimed at lowering costs across the U.S. healthcare system.

Powered by Yahoo Scout
  • Previous Close 36.62
  • Open 36.40
  • Bid 36.25 x 10000
  • Ask 36.33 x 110000
  • Day's Range 36.13 - 36.93
  • 52 Week Range 18.21 - 38.37
  • Volume 7,386,212
  • Avg. Volume 5,542,550
  • Market Cap (intraday) 42.37B
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) 60.60
  • EPS (TTM) 0.60
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date Nov 27, 2017
  • 1y Target Est 41.60

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

www.tevapharm.com

31,173

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

TEVA
16.50%
TA-125 (^TA125.TA)
14.92%

1-Year Return

TEVA
96.75%
TA-125 (^TA125.TA)
35.07%

3-Year Return

TEVA
269.51%
TA-125 (^TA125.TA)
126.58%

5-Year Return

TEVA
283.54%
TA-125 (^TA125.TA)
0.00%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 4.14B
Earnings -576M
Profit Margin -13.91%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
1B
2B
3B
4B
-10.0%
-5.0%
0.0%
5.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

33.00 Low
41.60 Average
36.36 Current
50.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/4/2026
Analyst UBS
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 42 -> 48

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.08%

  • Return on Assets (ttm)

    5.13%

  • Return on Equity (ttm)

    9.69%

  • Revenue (ttm)

    17.32B

  • Net Income Avi to Common (ttm)

    706M

  • Diluted EPS (ttm)

    0.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.66B

  • Total Debt/Equity (mrq)

    217.79%

  • Levered Free Cash Flow (ttm)

    2.22B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: